RxDoctor Payments Data

Israel Garcia

Nurse Practitioner · McAllen, TXNPI 1316518301

Payments from drug & device makers

$4,237in general payments, 2019–2025

Across 152 payments — averaging $27.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • GSK$1K
  • Baxter Healthcare$487
  • Sanofi$353
  • Mylan Specialty L.p.$214
  • Regeneron Healthcare Solutions, Inc.$190
  • plus $685 from 9 others

What the payments were for

  • Food & beverage$4,237100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,237 in reported general payments places this provider in the 90th percentile of 5,422 nurse practitioner providers in Texas.

See all nurse practitioner providers in Texas

Medicare billing

Part B allowed, 2024
$9,949
Medicare patients
61
Services billed
129

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab71$279,448
Trelegy ElliptaFluticasone/Umeclidin/Vilanter319$270,925
OfevNintedanib Esylate11$144,204
Breztri AerosphereBudesonide/Glycopyr/Formoterol56$36,817
Breo ElliptaFluticasone/Vilanterol54$28,662
Albuterol Sulfate HfaAlbuterol Sulfate244$10,690
Combivent RespimatIpratropium/Albuterol Sulfate21$10,019
Azelastine Hcl290$7,275
Montelukast Sodium482$5,164
Fluticasone Propionate141$2,416
Levocetirizine Dihydrochloride119$2,007
Ventolin HfaAlbuterol Sulfate15$839
Ropinirole Hcl68$572
Prednisone42$155
Azithromycin19$112

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$1,003$299,587373 claims
Boehringer IngelheimOfev, Combivent Respimat$44$154,22432 claims
AstraZenecaBreztri Aerosphere$1,306$36,81756 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,422 nurse practitioner providers in Texas.

Other nurse practitioner in McAllen

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →